PL408781A1 - Application of metallic platinum nanoparticles - Google Patents

Application of metallic platinum nanoparticles

Info

Publication number
PL408781A1
PL408781A1 PL408781A PL40878114A PL408781A1 PL 408781 A1 PL408781 A1 PL 408781A1 PL 408781 A PL408781 A PL 408781A PL 40878114 A PL40878114 A PL 40878114A PL 408781 A1 PL408781 A1 PL 408781A1
Authority
PL
Poland
Prior art keywords
platinum nanoparticles
application
metallic platinum
tumor
metallic
Prior art date
Application number
PL408781A
Other languages
Polish (pl)
Inventor
Marta Kutwin
Chwalibóg Ewa Sawosz
Jerzy Zygmunt Ostrowski
Anna Stefania Winnicka
Sławomir Jaworski
Mateusz Wierzbicki
Original Assignee
Szkoła Główna Gospodarstwa Wiejskiego w Warszawie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Szkoła Główna Gospodarstwa Wiejskiego w Warszawie filed Critical Szkoła Główna Gospodarstwa Wiejskiego w Warszawie
Priority to PL408781A priority Critical patent/PL408781A1/en
Publication of PL408781A1 publication Critical patent/PL408781A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Wynalazek dotyczy zastosowania koloidu nanocząstek metalicznej platyny do wytwarzania leku do leczenia nowotworów ośrodkowego układu nerwowego, zwłaszcza glejaka. Lek jest przeznaczony do podawania drogą bezpośredniej iniekcji do guza i/albo w bezpośrednią okolicę guza i/albo do krwi.The invention relates to the use of a colloid of metallic platinum nanoparticles in the manufacture of a medicament for the treatment of central nervous system cancers, especially glioma. The drug is intended for administration by direct injection into the tumor and / or in the immediate vicinity of the tumor and / or into the blood.

PL408781A 2014-07-07 2014-07-07 Application of metallic platinum nanoparticles PL408781A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL408781A PL408781A1 (en) 2014-07-07 2014-07-07 Application of metallic platinum nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL408781A PL408781A1 (en) 2014-07-07 2014-07-07 Application of metallic platinum nanoparticles

Publications (1)

Publication Number Publication Date
PL408781A1 true PL408781A1 (en) 2016-01-18

Family

ID=55072252

Family Applications (1)

Application Number Title Priority Date Filing Date
PL408781A PL408781A1 (en) 2014-07-07 2014-07-07 Application of metallic platinum nanoparticles

Country Status (1)

Country Link
PL (1) PL408781A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021107794A1 (en) 2019-11-28 2021-06-03 Instytut Fizyki Jądrowej Im. Henryka Niewodniczańskiego Pan Method of making a system containing gold nanoparticles and use of the system in antitumor therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021107794A1 (en) 2019-11-28 2021-06-03 Instytut Fizyki Jądrowej Im. Henryka Niewodniczańskiego Pan Method of making a system containing gold nanoparticles and use of the system in antitumor therapy

Similar Documents

Publication Publication Date Title
JOP20200097A1 (en) Androgen receptor modulator and uses thereof
CY1122899T1 (en) AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
EA201691023A1 (en) PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
MX2018014175A (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE.
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112016012713A2 (en) METHOD FOR TREATMENT OF CANCER IN A PATIENT IN NEED, AND METHOD OF SELECTING A PATIENT FOR A METHOD OF TREATMENT
EA201692109A1 (en) OPTIONS OF ANTIBODIES TO FACTOR D AND THEIR APPLICATION
MX373231B (en) ANTICANCER AGENT.
BR112017018964A2 (en) use of plinabulin and methods to treat brain tumor
CY1122968T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
MX2023011202A (en) Rara agonists for the treatment of aml and mds.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EA201591450A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLYCOSAMINO GLYCAN
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
EA201691562A2 (en) FILTERS FOR INFUSION KITS
MX369090B (en) Sultiame for the treatment of sleep apnea.
TR201903234T4 (en) Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
PL414785A1 (en) 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance
UA88769U (en) Method for preventing and treating benign breast dysplasia in patients with early miscarriage